Drug intelligence / Profile preview

miR-1271-5p mimic

Development stage
Preclinical
Lead developer
RiboBio
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

miR-1271-5p mimic is a synthetic double-stranded RNA oligonucleotide designed to emulate the biological activity of the endogenous microRNA miR-1271-5p. Functioning as a tumor suppressor, it post-transcriptionally regulates gene expression by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to their degradation or translational repression. Preclinical research has demonstrated that miR-1271-5p mimic can inhibit cell proliferation, migration, and invasion while promoting apoptosis in various cancers, including acute myeloid leukemia (AML), hepatocellular carcinoma, colorectal cancer, and endometrial cancer. It achieves these effects by targeting oncogenic factors such as ZIC2, FOXK2, and PHF6. Currently, the mimic is primarily utilized as a research reagent and laboratory tool to investigate microRNA-mediated signaling pathways and potential therapeutic interventions in oncology.

Other names
microRNA-1271-5p mimicmicroRNA1271-5p mimicmicroRNA 1271-5p mimichsa-miR-1271-5p mimichsa-miR1271-5p mimichsa-miR 1271-5p mimicmiR-1271 mimicmiR1271 mimicmiR 1271 mimic
02

Targets

FOXK2 (Forkhead box protein K2)PI-PLC (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4)AQP5 (Aquaporin-5)Zinc finger protein ZIC 2 mRNA

Beyond the preview

Go deeper on miR-1271-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-1271-5p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call